Scarica l'app Stockscreener
17.75
4.55%
-0.845
Pre-mercato:
17.75
0.005
+0.03%
Precedente Chiudi:
$18.59
Aprire:
$18.97
Volume 24 ore:
1.18M
Relative Volume:
0.40
Capitalizzazione di mercato:
$819.84M
Reddito:
$82.71M
Utile/perdita netta:
$-102.24M
Rapporto P/E:
-4.8351
EPS:
-3.67
Flusso di cassa netto:
$-76.57M
1 W Prestazione:
-8.53%
1M Prestazione:
+29.43%
6M Prestazione:
+65.53%
1 anno Prestazione:
+18.38%
Intervallo 1D:
$17.45
$18.97
Intervallo di 1 settimana:
$17.07
$21.02
Portata 52W:
$3.42
$21.02
Urogen Pharma Ltd Stock (URGN) Company Profile
Nome
Urogen Pharma Ltd
Settore
Industria
Telefono
972 9 770 7601
Indirizzo
9 HA'TA'ASIYA ST, RA'ANANA
Confronta URGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
17.75 | 924.49M | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-16 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-05-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-04-16 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-19 | Ripresa | Ladenburg Thalmann | Buy |
| 2024-08-22 | Iniziato | Guggenheim | Buy |
| 2023-02-08 | Downgrade | Jefferies | Buy → Hold |
| 2022-04-27 | Iniziato | Berenberg | Buy |
| 2020-04-16 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-13 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-09 | Iniziato | National Securities | Neutral |
| 2019-05-30 | Iniziato | JP Morgan | Neutral |
| 2019-05-29 | Iniziato | Goldman | Neutral |
| 2019-01-29 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-08 | Ripresa | Jefferies | Buy |
| 2018-04-04 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-11-15 | Reiterato | Oppenheimer | Outperform |
| 2017-11-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
Mostra tutto
Urogen Pharma Ltd Borsa (URGN) Ultime notizie
The UroGen Pharma Ltd. (NASDAQ:URGN) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - simplywall.st
UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
UroGen Pharma's Q2 2025 Earnings: A Catalyst for Valuation Re-Rating in Uro-Oncology? - AInvest
UroGen Pharma Q2 2025 Earnings Call Transcript - AInvest
UroGen Pharma Ltd. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:URGN) - Seeking Alpha
Oppenheimer Maintains Buy Rating on Urogen Pharma with $31 Price Target - AInvest
UroGen Pharma Receives FDA Approval for ZUSDURI for Recurrent Bladder Cancer - MSN
Guggenheim raises UroGen Pharma stock price target to $32 on Zusduri launch - Investing.com Australia
UroGen Pharma Reports Q2 2025 Results and Launches ZUSDURI - TipRanks
UroGen Pharma Q2 Earnings Call: FDA Approval, Revenue Growth, and Expanded Sales Force - AInvest
UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ... - Yahoo Finance
UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA A - GuruFocus
UroGen Pharma Outpaces Forecasts With Revenue And FDA Nod - Finimize
Urogen Pharma Q2 2025 Earnings Call Transcript - MarketBeat
Health Care Stocks Slipped As Big Players Disappointed - Finimize
UroGen Pharma (URGN) Receives Consistent "Buy" Rating from D. Boral Capital | URGN Stock News - GuruFocus
Sector Update: Health Care - MarketScreener
UroGen Pharma Tops Revenue Forecasts With FDA Approval In Tow - Finimize
Earnings call transcript: UroGen Pharma Q2 2025 results show revenue growth - Investing.com
Earnings call transcript: UroGen Pharma Q2 2025 results show revenue growth By Investing.com - Investing.com South Africa
Urogen Pharma Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
UroGen Pharma falls as wider-than-expected Q2 loss overshadows revenue beat - Investing.com
UroGen Pharma earnings missed by $0.22, revenue topped estimates - Investing.com Australia
UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDUR - GuruFocus
Earnings Flash (URGN) UroGen Pharma Posts Q2 Net Loss $1.05 a Share, vs. FactSet Est of $0.83 Loss - MarketScreener
UroGen Pharma Ltd. SEC 10-Q Report - TradingView
Earnings Flash (URGN) UroGen Pharma Ltd. Reports Q2 Revenue $24.2M, vs. FactSet Est of $23.1M - MarketScreener
UroGen Pharma Expands Commercial Portfolio with Launch of - GlobeNewswire
UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results - Yahoo Finance
UroGen Pharma (URGN) Q2 Earnings Preview: Expectations and Revis - GuruFocus
UroGen Pharma (URGN) Q2 Earnings Preview: Expectations and Revisions - GuruFocus
UroGen’s Zusduri benefit maintained in NMIBC Phase III study - Yahoo Finance
URGN: D. Boral Capital Maintains Buy Rating and $25 Price Target - GuruFocus
D. Boral Capital Maintains Buy Rating for UroGen Pharma with $25 Price Target - AInvest
UroGen Pharma (URGN) Highlights Promising Long-Term Data for Bla - GuruFocus
URGN: D. Boral Capital Maintains Buy Rating and $25 Price Target | URGN Stock News - GuruFocus
UroGen Pharma (URGN) Highlights Promising Long-Term Data for Bladder Cancer Treatment - GuruFocus
UroGen Pharma: D. Boral Capital maintains Buy, PT raised to $25 from $25. - AInvest
UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer - GlobeNewswire
Breakthrough: New Bladder Cancer Drug Shows 72% Success Rate in Phase 3 Trial Results - Stock Titan
What institutional investors are buying UroGen Pharma Ltd. stockAchieve superior returns through strategic trading - Jammu Links News
How strong is UroGen Pharma Ltd. company’s balance sheetPhenomenal capital gains - Jammu Links News
What is UroGen Pharma Ltd. company’s growth strategyAchieve superior capital gains with smart trades - Jammu Links News
Does UroGen Pharma Ltd. stock perform well during market downturnsInvest confidently with professional advice - Jammu Links News
What are the technical indicators suggesting about UroGen Pharma Ltd.Rapid portfolio appreciation - Jammu Links News
Is UroGen Pharma Ltd. a growth stock or a value stockAchieve consistent profits with expert advice - Jammu Links News
Should I hold or sell UroGen Pharma Ltd. stock in 2025Unlock exclusive stock market forecasts - Jammu Links News
What markets is FTAIN expanding into Is UroGen Pharma Ltd. stock a good long term investment optionDouble or triple returns - Jammu Links News
What catalysts could drive UroGen Pharma Ltd. stock higher in 2025Build wealth steadily with proven investment techniques - Jammu Links News
How does UroGen Pharma Ltd. compare to its industry peersRetirement Planning Alerts That Work - Jammu Links News
Is UroGen Pharma Ltd. stock overvalued or undervaluedBreakout Stocks Strategy With Low Risk - jammulinksnews.com
Urogen Pharma Ltd Azioni (URGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.24%
3.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):